State Street Corp Akero Therapeutics, Inc. Transaction History

State Street Corp

$2.41 Trillion
Q3 2024

A detailed history of State Street Corp transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, State Street Corp holds 2,502,946 shares of AKRO stock, worth $78.1 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,502,946

Previous 2,689,426 6.93%

Holding current value

$78.1 Million

Previous $63.1 Million 13.81%

% of portfolio

0.0%

Previous 0.0%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$21.45 - $29.34 $4 Million - $5.47 Million	-186,480 Reduced 6.93%	2,502,946 $71.8 Million
Q2 2024 Aug 14, 2024	SELL	$18.31 - $24.62 $20.3 Million - $27.3 Million	-1,108,304 Reduced 29.18%	2,689,426 $63.1 Million
Q1 2024 May 15, 2024	SELL	$17.76 - $31.18 $23.5 Million - $41.3 Million	-1,325,165 Reduced 25.87%	3,797,730 $95.9 Million
Q4 2023 Feb 14, 2024	BUY	$11.38 - $50.33 $29.8 Million - $132 Million	2,617,047 Added 104.44%	5,122,895 $120 Million
Q3 2023 Nov 14, 2023	BUY	$41.19 - $52.25 $10.9 Million - $13.9 Million	265,617 Added 11.86%	2,505,848 $127 Million
Q2 2023 Aug 14, 2023	BUY	$36.89 - $56.88 $347,651 - $536,037	9,424 Added 0.42%	2,240,231 $105 Million
Q1 2023 May 15, 2023	SELL	$37.27 - $50.24 $10.1 Million - $13.6 Million	-270,162 Reduced 10.8%	2,230,807 $85.4 Million
Q4 2022 Feb 14, 2023	BUY	$33.44 - $54.8 $65.3 Million - $107 Million	1,953,347 Added 356.7%	2,500,969 $137 Million
Q3 2022 Nov 15, 2022	BUY	$10.15 - $34.05 $555,915 - $1.86 Million	54,770 Added 11.11%	547,622 $18.6 Million
Q2 2022 Aug 15, 2022	SELL	$8.0 - $15.01 $5.97 Million - $11.2 Million	-746,265 Reduced 60.23%	492,852 $4.66 Million
Q1 2022 May 16, 2022	BUY	$12.97 - $22.26 $2.68 Million - $4.6 Million	206,496 Added 20.0%	1,239,117 $17.6 Million
Q4 2021 Feb 14, 2022	SELL	$19.87 - $26.24 $2.41 Million - $3.19 Million	-121,480 Reduced 10.53%	1,032,621 $21.8 Million
Q3 2021 Nov 15, 2021	SELL	$18.65 - $25.46 $1.4 Million - $1.91 Million	-75,039 Reduced 6.11%	1,154,101 $25.8 Million
Q2 2021 Aug 16, 2021	BUY	$24.81 - $32.35 $7.17 Million - $9.35 Million	289,094 Added 30.75%	1,229,140 $30.5 Million
Q1 2021 May 17, 2021	BUY	$24.04 - $34.19 $2.7 Million - $3.83 Million	112,162 Added 13.55%	940,046 $27.3 Million
Q4 2020 Feb 16, 2021	BUY	$25.12 - $29.89 $15.3 Million - $18.2 Million	610,271 Added 280.44%	827,884 $21.4 Million
Q3 2020 Nov 10, 2020	BUY	$30.79 - $39.92 $924,408 - $1.2 Million	30,023 Added 16.0%	217,613 $6.7 Million
Q2 2020 Aug 14, 2020	BUY	$19.25 - $26.76 $1.32 Million - $1.84 Million	68,806 Added 57.93%	187,590 $4.68 Million
Q1 2020 May 11, 2020	BUY	$12.8 - $27.05 $1.52 Million - $3.21 Million	118,784 New	118,784 $2.52 Million

Others Institutions Holding AKRO

# of Institutions

190

Shares Held

73.8M

Call Options Held

241K

Put Options Held

647K

View Full List

About Akero Therapeutics, Inc.

Ticker AKRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,417,600
Market Cap $1.45B
Description
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...

More about AKRO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.

Account

State Street Corp Akero Therapeutics, Inc. Transaction History